Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Treating active rheumatoid arthritis with Janus kinase inhibitors

The ORAL Strategy trial1 by Roy Fleischmann and colleagues in The Lancet studied patients with active rheumatoid arthritis. They had all responded inadequately to methotrexate, the dominant conventional disease-modifying antirheumatic drug (DMARD). The key comparison in the trial was the effects of a combination of different treatments with methotrexate. One treatment was tofacitinib. This drug is an orally active Janus kinase (JAK) inhibitor, a relatively new type of drug for rheumatoid arthritis.